Business Wire

CO-VANTAGE-DATA-CENTERS

10.1.2023 14:01:55 CET | Business Wire | Press release

Share
Vantage Data Centers Enters London Market With £500 Million Investment

Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced its entrance into London with the development of a 48MW £500 million campus. In addition, the company has opened a second 40MW data center on its existing Cardiff campus.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230110005323/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Vantage Data Centers’ LHR1 campus will include 48MW of IT capacity across two facilities. (Photo: Business Wire)

Situated on nearly five acres (two hectares) in the PowerGate neighborhood of North Acton, an established data center community in the northwest part of the city, Vantage’s London campus will total 430,000 square feet (40,000 square meters) across two 24MW multi-story data centers once fully developed. The first facility will open its doors to hyperscale customers and cloud providers in late 2024, which will mark Vantage’s 11th campus in EMEA.

“Vantage has experienced rapid growth over the past three years as we continue developing state-of-the-art data center campuses across EMEA,” said Antoine Boniface, president, EMEA at Vantage Data Centers. “With London being one of the largest data center markets in the world, this expansion further solidifies Vantage’s role at the forefront of the digital infrastructure revolution. With relatively little inventory available in London and requirements on the rise, we are ideally positioned to deliver for our customers.”

London is the largest of the FLAP (Frankfurt, London, Amsterdam and Paris) data center markets, buoyed by the U.K.’s leadership in public cloud infrastructure adoption. Findings from Structure Research indicate that hyperscale data center offerings currently account for 48% of the London market, which is projected to grow to 66% by 2027, making this a key time for Vantage to enter the arena.

“The continuing demand for data centers in London offers a prime opportunity for Vantage Data Centers to make its entrance into the highly-coveted market,” said Tim Kay, deputy director for technology, Department for International Trade in London. “Vantage’s presence in London will play a key role in enabling leading technology enterprises with additional IT capacity to support digital transformation initiatives and cloud adoption.”

In addition to the development of its London campus, Vantage has completed the first phase (12MW) of a second 40MW facility at its growing Cardiff campus, located in Wales, the second largest data center market in the U.K. The new facility boasts one of the lowest power usage effectiveness (PUE) ratios across all of Vantage’s facilities thanks in part to its extremely energy efficient indirect evaporative free cooling system, which negates the need for compressors in the cooling cycle.

Once fully developed, the 46-acre campus (19 hectares) will include three data centers totaling 148MW across 2 million square feet (186,000 square meters). Conveniently located in the U.K.’s tech corridor near the M4 and just 100 miles (160 kilometers) from London’s urban density, the campus offers numerous connectivity options with low latency between Wales and London of less than 1.5 milliseconds. The sustainable campus operates entirely on renewable energy sources.

“We are delighted to welcome customers to our newest data center in Cardiff,” said Justin Jenkins, Vantage’s chief operating officer, Europe and president, U.K. “The significant investment Vantage is making in Wales is transforming the area into one of Europe’s leading data center hubs and a top cloud region in the U.K. This is great news for the local economy as the added capacity will attract more global companies to the region, ensuring additional work for hundreds of local contractors on site and creating new permanent job opportunities.”

In December 2021, Vantage opened a corporate office in the Farringdon district of Central London to support the company’s scaling operations across EMEA.

About Vantage Data Centers

Vantage Data Centers powers, cools, protects and connects the technology of the world’s well-known hyperscalers, cloud providers and large enterprises. Developing and operating across five continents in North America, EMEA and Asia Pacific, Vantage has evolved data center design in innovative ways to deliver dramatic gains in reliability, efficiency and sustainability in flexible environments that can scale as quickly as the market demands.

For more information, visit http://www.vantage-dc.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005323/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye